Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results...

Evenovia股價上漲，因公司宣佈將發佈其成功的第3期CPN-302研究Clobetasol丙酸醋酯懸浮液0.05%作爲治療眼部手術後炎症和疼痛的結果。結果...

Benzinga · 10/17 02:03

Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results Will Be Presented at the American Academy of Ophthalmology 2024 Expo.

Evenovia股票交易正在上漲，因爲公司宣佈將展示其成功的Clobetasol Propionate Suspension 0.05%第3期CPN-302研究結果，作爲眼部手術後治療炎症和疼痛的方法。結果將在2024年美國眼科醫療學會博覽會上展示。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。